Upcoming Studies

Below please find the list of our upcoming Studies:

Study Medication Study Major Inc / Criteria Sponsor Study Title
Budesonide/Albuterol metered dose inhaler Asthma
  • Age 4 years old and above
  • Diagnosis of Asthma for at least 1 year
  • Receiving asthma maintenance therapies
  • History of at least 1 severe asthma exacerbation within the last 12 months
 Avillion A long-term, randomized, double-blind, multicenter, parallel-group, phase III study evaluating the efficacy and safety of PT027 compared to PT007 administered as needed in response to symptoms in symptomatic adults and children 4 years of age or older with asthma (Mandala) / AV003

Study Study Major Inc / Criteria Sponsor Study Title
Asthma – Observational study Asthma
  • Age 18 years old and above
  • Diagnosis of severe asthma for at least 1 year
  • Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists) at the Investigator’s or sub-investigator’s site
  • Uncontrolled asthma despite receiving high-dose ICS with additional controllers, or use FDA-approved monoclonal antibodies or systemic corticosteroids or other systemic immunosuppressants for the treatment of severe asthma
 AstraZeneca A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.

Study Medication Study Major Inc / Criteria Sponsor Study Title
PF 04965842, a JAK kinase inhibitor oral tablet Atopic Dermatitis / Eczema
  • Age 12 to <18 years old
  • Have a diagnosis of chronic atopic dermatitis for at least 1 year
  • Have symptoms of moderate to severe AD when you enter the study
  • Have not responded to topical medications or needed systemic therapy to control their AD
 Pfizer A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with hereditary angioedema.

Study Medication Study Major Inc / Criteria Sponsor Study
BCX7353, an oral tablet Hereditary Angioedema (HAE)
  • Age 12 years old and above
  • Have been diagnosed with HAE Type 1 or 2
  • Have access to and take their own prescribed on-demand acute attack medications (either at home or in a medical setting)
 BioCryst An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with type I and II hereditary angioedema

Study Name Study Medication Major Inc / Criteria Sponsor Study Title
Hereditary Angioedema (HAE) – pediatric prophylactic treatment Takhzyro (Lanadelumab), anti-plasma kallikrein monoclonal antibody injection
  • Age between 2 and < 12 years old at the time of study enrollment
  • Have a confirmed diagnosis of Hereditary Angioedema type I or II
  • Have at least one HAE attack per three months
 Takeda / Shire An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age

Study Name Study Medication Major Inc / Criteria Sponsor Study Title
Hereditary Angioedema (HAE) – acute treatment CSL312, Factor XIIa antagonist monoclonal antibody injection CSL Behring LLC The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, treatment patterns and Health Outcomes of Individuals with Severe Asthma in the United States.

Study Name Study Medication Major Inc / Criteria Sponsor Study Title
Hereditary Angioedema (HAE) – observational study
  • Diagnosis of HAE Type I or Type II
  • Ability to use a mobile device for data collection in the study
 Takeda / Shire the EMPOWER study
An observational, non-interventional, study of patients with hereditary angioedema in the United States and Canada (EMPOWER study)

Study Name Study Medication Major Inc / Criteria Sponsor Study Title
Hereditary Angioedema (HAE)
  • Age 2 years old and above
  • Confirmed or suspected to have HAE
 CSL Behring LLC SAIRB-18-0006
Genetic profiling for patients with hereditary angioedema

Study Name Study Medication Major Inc / Criteria Sponsor Study Title
Peanut Allergy – Investigator Initiated Study
  • Age between 6 months to 17 years old
  • Peanut allergic subjects or healthy controls
 CSL Behring LLC